Efficacy and Safety of Ustekinumab, a Human Monoclonal Anti-IL-12/IL-23 Antibody, in Patients With Behçet Disease
Clinical trial NCT02648581 · COMPLETED
Trial details
- NCT number
- NCT02648581
- Sponsor
- Assistance Publique - Hôpitaux de Paris
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2017-06-14
- Primary completion
- 2019-05-07
- Enrollment
- 16
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.